chevron_leftBack
As of 24 April 2025, MediWound Ltd. has a market cap of $194.21M USD, ranking #17339 globally and #36 in Israel. It ranks #1722 in the Healthcare sector, and #480 in the Biotechnology industry.
Key Stats
Market Cap
$194.21MUSD
Enterprise Value
$157.98MUSD
Revenue (TTM)
$20.22MUSD
EBITDA (TTM)
-$18.58MUSD
Net Income (TTM)
-$30.22MUSD
EBITDA Margin
-92%
Profit Margin
-149%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Ofer Gonen
open_in_new
Employees
111
Founded
2000
IPO
20 Mar 2014
Website
mediwound.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.1% | 10% | 10% | -2.6% | 4.2% | 14% |
Upcoming Earnings
Earnings Date
Wed, May 28
Earnings Time
sunny
Before Open
EPS Estimate
-$0.5600
Revenue Estimate
$5.43M
9.4% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
MDWD
MediWound Ltd
ISIN: IL0011316309
Shares Out.:
Shares Outstanding:
10.808M1
Shares Float:
7.246M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
17.93 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
